Physician profile
Amy Dixon Farmer
NPI 1588383574
$7,073.29
in general payments reported to CMS, 2019-2025
26 companies · $2,503 in 2025
The $2,503 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,058 · 2024: $2,512 · 2025: $2,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,919 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,919.24 |
| Education | $154.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,970.02 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $967.96 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $507.38 | 2023-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $491.83 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $455.70 | 2023-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $400.93 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $322.17 | 2024-2025 | Vowst, Zenpep |
| Qol Medical, LLC | $264.13 | 2023-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $248.22 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $203.70 | 2023-2025 | Linzess |
| Pfizer INC. | $180.60 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $172.78 | 2024-2025 | Voquezna |
| Celgene Corporation | $121.17 | 2023-2024 | Zeposia |
| Gilead Sciences, INC. | $118.93 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $107.34 | 2025 | Dupixent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $100.00 | 2023-2025 | Rebyota, Cimzia |
| Janssen Scientific Affairs, LLC | $80.22 | 2025 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $70.51 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $65.01 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $55.05 | 2024 | Zymfentra |
| Nestle Healthcare Nutrition INC. | $53.67 | 2023 | |
| Intercept Pharmaceuticals, INC. | $39.66 | 2025 | |
| Mauna Kea Technologies, INC. | $29.21 | 2024 | |
| Amgen INC. | $17.56 | 2023 | Amjevita, Avsola |
| Organon LLC | $16.35 | 2023 | Hadlima |
| Braintree Laboratories, INC. | $13.19 | 2023 | Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Farmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.